Erythropoietin treatment improves liver regeneration and survival in rat models of extended liver resection and living donor liver transplantation
Standard
Erythropoietin treatment improves liver regeneration and survival in rat models of extended liver resection and living donor liver transplantation. / Bockhorn, Maximilian; Fingas, Christian D; Rauen, Ursula; Canbay, Ali; Sotiropoulos, Georgios C; Frey, Ulrich; Sheu, Shin-Yi; Wohlschläger, Jeremias; Broelsch, Christoph E; Schlaak, Jörg F.
in: TRANSPLANTATION, Jahrgang 86, Nr. 11, 15.12.2008, S. 1578-85.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Erythropoietin treatment improves liver regeneration and survival in rat models of extended liver resection and living donor liver transplantation
AU - Bockhorn, Maximilian
AU - Fingas, Christian D
AU - Rauen, Ursula
AU - Canbay, Ali
AU - Sotiropoulos, Georgios C
AU - Frey, Ulrich
AU - Sheu, Shin-Yi
AU - Wohlschläger, Jeremias
AU - Broelsch, Christoph E
AU - Schlaak, Jörg F
PY - 2008/12/15
Y1 - 2008/12/15
N2 - BACKGROUND: Inadequate liver regeneration is still an unsolved problem in major liver resection and living donor liver transplantation (LDLT). Therefore, we have investigated the use of erythropoietin (EPO) as an exogenous stimulator of liver regeneration in rat models of liver resection and LDLT.METHODS: Rats were treated with EPO or heat-inactivated EPO-vehicles. Animals underwent 70% or 90% partial hepatectomy (PH) or 30% partial liver transplantation (pLTx). Serum and liver samples were taken to investigate liver function, liver-to-body weight ratio (LBWR), hepatocyte-proliferation (Ki-67), apoptosis (terminal deoxynucleotide transferase-mediated dUTP nick-end labeling-assay), proregenerative cytokines (interleukin [IL]-6/tumor necrosis factor-alpha), and angiogenesis. Gene expression was assessed by in-house cDNA array and quantitative real-time polymerase chain reaction. As clinical parameters, LBWR and overall survival were determined.RESULTS: Erythropoietin led to improved liver regeneration as shown by an increased LBWR/Ki-67 after PH and pLTx. Liver damage, indicated by the serum activity of aspartate aminotransferase, alanine aminotransferase, and glutamate dehydrogenase was reduced after PH. After surgery EPO treatment induced modulation of c-jun, IL-6, p53, and the antiapoptotic gene Bcl-XL, which was accompanied by a decreased apoptosis rate (0.56% vs. 1.03%; P<0.04). IL-6 production was increased at 12 hr, although no effects could be found concerning tumor necrosis factor-alpha production and angiogenesis. In addition, EPO-treated rats showed a significantly improved 28-day survival after 90% PH (92% vs. 67%) and pLTx (88% vs. 38%).CONCLUSIONS: Erythropoietin treatment significantly improved liver regeneration and survival after PH and pLTx and may therefore represent a promising strategy to optimize the clinical outcome after extended liver resection and LDLT in the future.
AB - BACKGROUND: Inadequate liver regeneration is still an unsolved problem in major liver resection and living donor liver transplantation (LDLT). Therefore, we have investigated the use of erythropoietin (EPO) as an exogenous stimulator of liver regeneration in rat models of liver resection and LDLT.METHODS: Rats were treated with EPO or heat-inactivated EPO-vehicles. Animals underwent 70% or 90% partial hepatectomy (PH) or 30% partial liver transplantation (pLTx). Serum and liver samples were taken to investigate liver function, liver-to-body weight ratio (LBWR), hepatocyte-proliferation (Ki-67), apoptosis (terminal deoxynucleotide transferase-mediated dUTP nick-end labeling-assay), proregenerative cytokines (interleukin [IL]-6/tumor necrosis factor-alpha), and angiogenesis. Gene expression was assessed by in-house cDNA array and quantitative real-time polymerase chain reaction. As clinical parameters, LBWR and overall survival were determined.RESULTS: Erythropoietin led to improved liver regeneration as shown by an increased LBWR/Ki-67 after PH and pLTx. Liver damage, indicated by the serum activity of aspartate aminotransferase, alanine aminotransferase, and glutamate dehydrogenase was reduced after PH. After surgery EPO treatment induced modulation of c-jun, IL-6, p53, and the antiapoptotic gene Bcl-XL, which was accompanied by a decreased apoptosis rate (0.56% vs. 1.03%; P<0.04). IL-6 production was increased at 12 hr, although no effects could be found concerning tumor necrosis factor-alpha production and angiogenesis. In addition, EPO-treated rats showed a significantly improved 28-day survival after 90% PH (92% vs. 67%) and pLTx (88% vs. 38%).CONCLUSIONS: Erythropoietin treatment significantly improved liver regeneration and survival after PH and pLTx and may therefore represent a promising strategy to optimize the clinical outcome after extended liver resection and LDLT in the future.
KW - Animals
KW - Cell Proliferation
KW - Erythropoietin
KW - Hepatectomy
KW - Hepatocytes
KW - Liver
KW - Liver Regeneration
KW - Liver Transplantation
KW - Male
KW - Models, Animal
KW - Oligonucleotide Array Sequence Analysis
KW - Rats
KW - Rats, Inbred Lew
KW - Recombinant Proteins
KW - Reverse Transcriptase Polymerase Chain Reaction
KW - Treatment Outcome
U2 - 10.1097/TP.0b013e31818b22b4
DO - 10.1097/TP.0b013e31818b22b4
M3 - SCORING: Journal article
C2 - 19077893
VL - 86
SP - 1578
EP - 1585
JO - TRANSPLANTATION
JF - TRANSPLANTATION
SN - 0041-1337
IS - 11
ER -